Healthcare Technology Startup Emme Bags $2.5 Million Seed Fund

Healthcare Technology Startup Emme Bags $2.5 Million Seed Fund

Emme, a healthcare technology company focused on women's health, announces an influx of $2.5 million in Seed Funding, led by Magnetic Ventures with participation from existing investors. As a part of the deal, Magnetic founding partner Christine Aylward, joined the board, along with healthcare innovator & Evidation’s CEO, Deborah Kilpatrick.  

On the occasion, the company also launched an integrated solution designed to reduce the nine percent failure rate of birth control pills called Emme Smart Case, which according to the company is an integrated system that uses patent-pending, multi-sensor technology to track when pills are taken. Emme claims that the solution removes the burden of remembering to take the pill and notifies at-risk users when back-up contraception is needed, while also being compatible with more than 100 brands of birth control pills.

“Missed pills result in nearly one million unplanned pregnancies in the United States each year. They also disrupt hormone balance causing side effects such as bleeding, nausea, mood changes, and headaches. After hearing stories from hundreds of women about the stress of the pill, I knew we could help improve the effectiveness of the pill by solving the problem of adherence with technology,” states Amanda French, who along with Janene Fuerch co-founded Emme in 2017.

The smart case syncs with the app to send persistent customized reminders until the dose is taken. It also revealed that in beta testing, stating that the solution drove an 80 percent reduction in missed pills, while 85 percent of participants reported improved confidence with the pill.

In a statement, Christine said, “Emme is the first company to offer a comprehensive and complete birth control solution. Many companies deliver pills, but no other company can tell you when to take the pill, and when you should use back-up contraception to help avoid getting pregnant. It may seem simple to be compliant with pill management - but pregnancy rates while on the oral contraception prove it's not.”